Clinical Data With Pacritinib in Patients With Myelofibrosis

Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.

Related Keywords

, Data With Pacritinib , Patients With Myelofibrosis , Myelofibrosis , Mf Cancer , Primary Myelofibrosis , Pacritinib , Jak Inhibitors , Jak Inhibition , Novel Therapy , Persist2 , Persist 2 Trial , Persist 2 Study , Irak , Irak Signaling , Clinical Trials , Patient Selection , Patient Eligibility , Fedratinib , Ruxolitinib , Pacifica Trial , Pacifica Study ,